203047-36-3

Upstream product

• 2417-73-4 methyl 2-bromomethylbenzoate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1124216-23-4 methyl 3-((4-(4-(3-phenylureido)benzoyl)piperazin-1-yl)methyl)benzoate 
• 1124216-26-7 3-((4-(4-(3-phenylureido)benzoyl)piperazin-1-yl)methyl)benzoic acid 
• 1124216-18-7 1-(4-(1-(3-((1-(hydroxymethyl)cyclopentyl)carbamoyl)benzyl)piperazine-4-carbonyl)phenyl)-3-phenylurea 2,2,2-trifluoroacetate 
• 500013-38-7 tert-Butyl 4-(3-carboxybenzyl)piperazine-1-carboxylate 

Relevant academic research and scientific papers

LPAR1 Inhibitor. Medical application and preparation method thereof

LPAR1 Inhibitor, medical application and preparation method thereof, and the structural general formula I of the inhibitor is as follows. In-flight RX Alkyl groups selected from H, C1 - C6, COOCH3 , CF3 , NO2 ,

benzamide derivatives as oxytocin agonists and vasopressin antagonists

Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or Via receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.